Equities analysts expect Acorda Therapeutics Inc (NASDAQ:ACOR) to report earnings of $0.01 per share for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Acorda Therapeutics’ earnings. The lowest EPS estimate is ($0.34) and the highest is $0.25. Acorda Therapeutics posted earnings per share of $0.43 during the same quarter last year, which would suggest a negative year over year growth rate of 97.7%. The company is expected to issue its next earnings results on Tuesday, October 30th.
On average, analysts expect that Acorda Therapeutics will report full-year earnings of $0.48 per share for the current year, with EPS estimates ranging from ($0.05) to $1.13. For the next year, analysts expect that the business will post earnings of ($3.76) per share, with EPS estimates ranging from ($4.35) to ($2.74). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Acorda Therapeutics.
Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.90. The company had revenue of $153.30 million for the quarter, compared to the consensus estimate of $138.63 million. Acorda Therapeutics had a negative net margin of 26.87% and a positive return on equity of 8.19%. Acorda Therapeutics’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.29 EPS.
In related news, major shareholder Scopia Capital Management Lp sold 143,576 shares of Acorda Therapeutics stock in a transaction dated Thursday, October 11th. The shares were sold at an average price of $16.98, for a total transaction of $2,437,920.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Burkhard Blank sold 6,250 shares of Acorda Therapeutics stock in a transaction dated Wednesday, August 1st. The stock was sold at an average price of $24.69, for a total transaction of $154,312.50. Following the transaction, the insider now directly owns 34,400 shares of the company’s stock, valued at $849,336. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 750,672 shares of company stock valued at $16,623,449. 7.80% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the stock. NumerixS Investment Technologies Inc boosted its stake in shares of Acorda Therapeutics by 123.5% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 3,800 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 2,100 shares during the period. Public Employees Retirement System of Ohio purchased a new position in shares of Acorda Therapeutics during the 2nd quarter worth about $132,000. Xact Kapitalforvaltning AB purchased a new position in shares of Acorda Therapeutics during the 1st quarter worth about $206,000. Dynamic Technology Lab Private Ltd purchased a new stake in Acorda Therapeutics in the 2nd quarter valued at about $218,000. Finally, Crossmark Global Holdings Inc. purchased a new stake in Acorda Therapeutics in the 2nd quarter valued at about $229,000.
Shares of Acorda Therapeutics stock traded up $0.13 during trading hours on Monday, reaching $17.68. The company’s stock had a trading volume of 587,654 shares, compared to its average volume of 651,743. Acorda Therapeutics has a one year low of $15.60 and a one year high of $36.35. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.56. The company has a market cap of $933.06 million, a PE ratio of 17.00 and a beta of 1.52.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.
Featured Story: How Do You Calculate Return on Equity (ROE)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.